Reuters logo
8 个月内
BRIEF-GSK's Mepolizumab meets endpoints in phase 3 EGPA study
2016年11月23日 / 早上7点16分 / 8 个月内

BRIEF-GSK's Mepolizumab meets endpoints in phase 3 EGPA study

1 分钟阅读

Nov 23 (Reuters) - Glaxosmithkline Plc :

* Mepolizumab meets endpoints in phase 3 egpa study

* Phase lll study of mepolizumab meets co-primary endpoints and all secondary endpoints in patients with eosinophilic granulomatosis with polyangiitis

* Mepolizumab is not approved for use anywhere in world for EGPA.

* Will support GSK's plans to submit regulatory applications for this patient population, expected in 2017 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 80 6749 1136)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below